Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
NHS cannot keep up with ‘tidal wave’ of demand for weight-loss jabs
The NHS cannot meet the “tidal wave” of demand for weight-loss jabs, medics say. A report calling for a review of existing treatment services has been backed by more than 200 healthcare professionals, ...
Unemployed to be given weight-loss jab to help them back into work
The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under brand name Mounjaro ...
Could weight-loss drugs get people back to work? UK wants to find out
Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.
Obesity care ‘insufficient’ as patients wait up to five years for care – report
Support for people living with obesity is “insufficient”, experts have said after a new report revealed that some patients ...
E!13h
Fat Joe Shares How Ozempic Helps Him Maintain 200-Pound Weight Loss
Rapper Fat Joe recently shared how he’s been using the Type 2 diabetes medication Ozempic to maintain his 200-pound weight ...
Everyday Health14h
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Employers are leaving out a coveted benefit as their health plan costs soar
Providing coverage for weight-loss drugs such as Wegovy and Ozempic is forcing employers to make some critical decisions.
Ozempic Butt Isn't The Strangest Side Effect Of The Drug. Here's What Else To Expect.
Taking Ozempic can cause nausea, diarrhea, vomiting, and potential muscle loss. Here, doctors share common and uncommon side ...
Healthy Returns: Covering weight loss drugs could cost Medicare $35 billion through 2034
Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...
Euro Weekly News15h
Mounjaro, Ozempic, and Wegovy: A review of weight-loss drugs and jabs in the UK and Europe
This article delves into the pros and cons of these drugs, addressing potential side effects (including the rare ones).
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...